Navigation Links
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Date:2/10/2012

SAN DIEGO, Feb. 10, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of transrenal molecular diagnostics, has announced that Stephen Zaniboni has been named Chief Financial Officer.

Mr. Zaniboni's experience includes raising more than $500 million through venture financing and IPO proceeds.  Mr. Zaniboni previously served as Chief Financial Officer of healthcare software solutions company Awarepoint and XIFIN Inc., a provider of revenue cycle management for diagnostic service providers. Mr. Zaniboni has also served as Chief Financial Officer of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Mr. Zaniboni played an important role in the sale of AviaraDx to bioMerieux, which continues to operate the company under the name bioTheranostics. Before AviaraDx, Mr. Zaniboni served as CFO of Arcturus Bioscience Inc., where he played an important role in the sale of Arcturus' life science business assets to Molecular Devices Inc. Prior to Arcturus, from 1997 to 2005; Mr. Zaniboni served as Chief Financial Officer of Sequenom  where he lead the efforts behind a very successful IPO. Mr. Zaniboni is co-founder of Sorrento Therapeutics, Inc. and served as a member of its board of directors until 2011. He was a practicing CPA with Arthur Andersen and holds a B.S. in accounting from Boston University and an M.B.A. from Boston College. 

"I am pleased that Steve joins our team to lead the transition of Trovagene from a research stage organization to a commercial enterprise," states Antonius Schuh, Ph.D.,  Trovagene's Chief Executive Officer. "This transition requires an experienced Chief Financial Officer with a successful track record of raising capital, building organizations and creating value for shareholders. I look forward to working with him again."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patente
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Call Stephen Michnick a gene grammarian
2. American Society for Microbiology honors J. Stephen Dumler
3. Stephen Maturo, M.D., ear, nose and throat specialist, receives Charles Ferguson Award
4. 2011 Stephen H. Schneider Symposium
5. FSU joins coalition working to improve nations power grid
6. GEN joins Charles Darwin 2009 celebration
7. Genomatix joins Illumina-Connect program
8. Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant
9. Mycotoxin Research joins Springers life sciences journals program
10. Anatomical Science International joins Springers publishing program
11. DEIMOS joins MARS and its satellite of instruments on seafloor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... X syndrome (FXS) is the most common hereditary form ... from attention deficit and/or hyperactivity disorder (ADHD), which complicates ... medication such as Ritalin is often successfully used to ... it is effective in children with mental retardation, it ...
... choose the nesting location of their first breeding season has ... a new University of Maryland/National Zoo study of the ... in their first year may help determine where they breed ... significantly affect the population as climate change makes their winter ...
... January 2001, the world held its breath when the tanker ... and began breaking up in the heart of one of ... the Galapagos Islands. At risk were vast numbers of ... Charles Darwin that contributed to his landmark theory of evolution ...
Cached Biology News:Effective ADHD treatment found for children with fragile X syndrome 2Early environment may be key to determining bird migration location 2Early environment may be key to determining bird migration location 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , Shareholders ... , Call by over 18% of ... Significant funding shortfall identified in the Progen merger proposal , ... Late last week Progen Pharmaceuticals Limited (ASX: PGL) responded to the requisitioning ...
... Clinics of Excellence, LLC, the nation,s only physician-driven ... its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 ... 4th Annual Community Oncology Conference today. "Our 200+ ... to launch the protocols across its network in ...
... Feb. 6 Stereotaxis, Inc. (Nasdaq:, STXS ) ... for the,fourth quarter and full year ended December 31, ... The Company will host a conference call and,webcast on ... to discuss,the Company,s fourth quarter results and current corporate ...
Cached Biology Technology:Cytopia and Other Progen Shareholders Maintain Call for Meeting 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 3Cytopia and Other Progen Shareholders Maintain Call for Meeting 4Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol 2Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2
Standard Fluka For microscopy (Bact., Hist.)...
Request Info...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Special grade: for electrophoresis...
Biology Products: